BTAI is in a challenging situation with respect to BXCL 701 (talabostat), the oncology asset now at the heart of its immuno-oncology subsidiary, Onkosxcel because talabostat is a prior art compound not discovered by Onkosxcel or BTAI (FIG. 1).

The active ingredient in BTAI's platform in a drug, Igalmi (BXCL 501), is the drug dexmedetomidine, which has been available since 1999 and is now used for intravenous administration before intubation. It is available under the brand Precedex, which is available as a generic ( https://www.drugs.com/price-guide/precedex ). It's chemical structure is well known^1.

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers such as prostate cancer and ovarian cancer Several smid-cap biopharmas are presenting data at ASCO-GU, including final results from BTAI We have also determined additional upcoming late stage trials in GU cancers in the next year   ASCO-GU 2023 starts February 16 and focuses on new and innovative findings and studies for the treatment of ge

First posted 1/19/2023; last updated 3/1/23

Summary: Biogen and Eisai's asset Lecanemab has a PDUFA date set for Friday 1/6/23 Lecanemab targets and effectively reduces beta-amyloid...

Summary:

(Posted 10:20am CST) $XBI $80.99 | -0.17% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

(Posted 10:20am CST) $XBI $80.99 | -0.17% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

The 40th Annual J.P. Morgan Health Care Conference is taking place fully online from January 10-13, 2022. "This premier conference is...